Print ISSN:-2394-4781

Online ISSN:-2394-4994

CODEN : IJCACT




Downlaod Files

   


Article Access statistics

Viewed: 1350

PDF Downloaded: 475


Dexmedetomidineas an adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block


Full Text PDF Share on Facebook Share on Twitter


Original Article

Author Details : Vipin Kumar Dhama, Anurag Agrawal, Subhash, Lokesh Kumar, Dheeraj Kumar Goel, Ashutosh Anshu

Volume : 2, Issue : 4, Year : 2015

Article Page : 222-226


Suggest article by email

Get Permission

Abstract

The study was done to evaluate the effect of two different doses of dexmedetomidine with ropivacainein classical supraclavicular brachial plexus blockade (posterolateral to subclavian artery). After randomization, 40 patients were divided into group A and group B having 20 patients each. In group A, 25 ml of ropivacaine (0.75 %) with 25 microgram of dexmedotmidine & in group B, 50 microgram of dexmedotmidine with 25 ml of ropivacaine (0.75 %) was given. Results showed that the mean sensory onset time in group A was 7.25 ± 5.95 min. & in group B was 8 ± 5.71 min. Mean motor block  onset time in group A was 18.5 ± 5.15 min. in group B, 14.5 ± 5.35 MIN. effective analgesia duration in group A  was 10.3±2.93 hour,and in a group B, 15.4 ±5.44 hour. Dexmedetomidine 25 microgram is a better combination since onset of sensory block is equally fast as with 50 microgram and negligible incidence of hypotension and bradycardia and nausea as compared to addition of 50 microgram.

Key words: Supraclavicular brachial plexus block, Ropivacaine, Dexmedetomidine



How to cite : Dhama V K, Agrawal A, Subhash, Kumar L, Goel D K, Anshu A, Dexmedetomidineas an adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block. Indian J Clin Anaesth 2015;2(4):222-226


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.